Literature DB >> 6231379

Depo-Provera--ethical issues in its testing and distribution.

M Potts, J M Paxman.   

Abstract

Ethical issues relating to the use of the injectable contraceptive in developed and developing countries alike involve public policy decisions concerning both criteria for testing a new drug and individual choices about using a specific form of contraception approved for national distribution. Drug testing consists of an important but still evolving set of procedures. Depo-Provera is not qualitatively different from any other drug and some unpredictable risks are inevitable, even after extensive animal experiments and clinical trials. In assessing the risks and benefits of Depo-Provera use, epidemiological data from large-scale human use is now beginning to become more important than data from animal experiments and clinical trials. The consumer's best interest is central to any ethically responsible system of drug distribution. Systems of informed choice are needed, even in societies where illiteracy remains common and medical services are weak. In the case of a contraceptive, the risks of non-use leading to unintended pregnancy, which can result in high mortality, are relevant as well as the side-effects of the method. An attempt, therefore, is made here to categorise those issues which are universal and those which are country-specific.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research; Genetics and Reproduction; Health Care and Public Health; Philosophical Approach; Behavior; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Agents, Progestin--beneficial effects; Contraceptive Agents--beneficial effects; Contraceptive Distribution; Contraceptive Methods; Decision Making; Depo-provera--beneficial effects; Distributional Activities; Endocrine System; Ethics; Evaluation; Evaluation Methodology; Family Planning; Hormones; Informed Consent; Injectables; Measurement; Medroxyprogesterone Acetate; Organization And Administration; Physiology; Political Factors; Program Activities; Programs; Reproductive Control Agents; Research Methodology; Testing

Mesh:

Substances:

Year:  1984        PMID: 6231379      PMCID: PMC1374922          DOI: 10.1136/jme.10.1.9

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  14 in total

1.  Statistical lives and the principle of maximum benefit.

Authors:  A Weale
Journal:  J Med Ethics       Date:  1979-12       Impact factor: 2.903

2.  Use of progestational agents in endometrial adenocarcinoma.

Authors:  J C Rozier; P B Underwood
Journal:  Obstet Gynecol       Date:  1974-07       Impact factor: 7.661

3.  Prognosis for the development of new chemical birth-control agents.

Authors:  C Djerassi
Journal:  Science       Date:  1969-10-24       Impact factor: 47.728

4.  A fifth freedom?

Authors:  D Baird
Journal:  Br Med J       Date:  1965-11-13

Review 5.  A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate.

Authors:  I S Fraser; E Weisberg
Journal:  Med J Aust       Date:  1981-01-24       Impact factor: 7.738

6.  Plasma levels and pharmacokinetics of ethynyl estrogens in various populations: II. Mestranol.

Authors:  J W Goldzieher; T S Dozier; A de la Pena
Journal:  Contraception       Date:  1980-01       Impact factor: 3.375

7.  Taking liberties with women: abortion, sterilization, and contraception.

Authors:  W Savage
Journal:  Int J Health Serv       Date:  1982       Impact factor: 1.663

8.  Depo-Provera and contraceptive risk: a case study of values in conflict.

Authors:  C Levine
Journal:  Hastings Cent Rep       Date:  1979-08       Impact factor: 2.683

9.  Medroxyprogesterone acetate and homozygous sickle-cell disease.

Authors:  K De Ceulaer; C Gruber; R Hayes; G R Serjeant
Journal:  Lancet       Date:  1982-07-31       Impact factor: 79.321

10.  Return of fertility after discontinuation of depot medroxyprogesterone acetate and intra-uterine devices in Northern Thailand.

Authors:  T Pardthaisong; R H Gray; E B McDaniel
Journal:  Lancet       Date:  1980-03-08       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.